2 results
Approved WMORecruiting
The aim is to see whether intradialytic parenteral nutrition is an efective treatment against the loss of muscle mass
Approved WMOPending
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.